The profile of tibolon with regard to breast safety in long-term therapy
Authors:
MUDr. Petrovičová Zuzana 1; prim. MUDr. Tibor Bielik; Ph.D. 2; MUDr. Milica Piškaninová 3
Authors‘ workplace:
privátna gynekologická ambulancia
Banská Bystrica
1; gyn. -pôr. odd. FNsP FDR
Banská Bystrica
2; Organon, Bratislava
3
Published in:
Prakt Gyn 2006; 10(3): 111-114
Overview
Hormonal substitution during menopause has a dramatic impact on the quality of life of women. Conventional hormonal therapy increases the incidence of mastodynia and MG density. Great stress is therefore laid on the selection of a preparation which has a minimum impact on MG density and on subjective feelings of patients when long-term use of hormone replacement therapy is necessary. The longitudinal retrospective study assessed 25 women taking tibolon for 36–119 months as compared with mammographic findings in women who had finished taking tibolon 36 months before. No difference was found between mammographic findings in women receiving long-term tibolon therapy and those in women who had finished taking tibolon. Tibolon appears to be a modality of postmenopause hormone replacement therapy which is well tolerated by patients even in cases where long-term therapy is necessary.
Key words:
tibolon – mammographic density – mastodynia
Sources
1. Bundred N. Hormone replacement therapy, breast cancer and the future, J Br Menopause Soc 2001; 13–15.
2. Eden J. The need for tissue selective menopausal agents. Gynecol Endocrinol 2005; 21: 22–27.
3. Gompel A, Kandouz M, Siromachkova M et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997; 11: 77–79.
4. Helmond FA. Livial and its tissue specific effects on breast tissue. J Menopause 2001; 8: 19–20.
5. Jaminch. Treatment of menopause and breast in practice. J Menopause 2001; 8: 21–23.
6. Petrovičová Z, Bielik T, Piškaninová M. Bezpečnostný profil tibolonu z aspektu prsníka pri prechode z krátkodobého režimu na dlhodoby režim užívania. Slov Gynekol a Pôrod. 2002; 9: 175–179.
7. Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas 2004; www.sciencedirect.com.
8. Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004; www.sciencedirect. com.
9. Lundstrome E. Effects of tibolone and continuous combined hormone replacement th. on mammography breast density. J Am Obstet Gynecol 2000; 186: 717–721.
10. Pasqualini JR. Synthesis and regulation of sex hormones in breast tissue during pre and postmenopause. J Menopause 2001; 8: 10–13.
11. Recommendations for Estrogen and Progestogen Use in Peri- and Postmenopausal Women. The North American Menopause Society 2004.
12. Reed MJ. Role of enzymes and tissue-specific actions of steroids. Maturitas 2004; available online at www.sciencedirect.com.
13. Santen R. Menopausal hormone therapies. Gyneol Endocrynol 2005; 21: 12–16.
14. Speroff L. The meaning of mammography breast density in users of postmenopausal hormone therapy; Maturitas 2002; 42: 31–35.
15. Valdivia I, Ortega D. A one year evaluation on mammary radiographic density (MxDx) changes with different HRTs regimens in climacteric woman. Acta Obstet Gynaecol Scand 1997; 76.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2006 Issue 3
Most read in this issue
- Ureaplasma Urealyticum as a Cause of Chronic Vaginal Discharge
- New gyneco-urological and sexological implications of the female prostate and female prostate specific antigen
- The possibility of donated gametes or embryos usage in infertility treatment
- The profile of tibolon with regard to breast safety in long-term therapy